drugset / Trial / NCT01294007

Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF)

NCT01294007 ↗

Terminated 1 enrolled Alphatec Spine, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the rate and quality of fusion of PureGen Osteoprogenitor Cell Allograft, compared to autograft bone in instrumented posterolateral fusion (PLF) procedures.

Timeline

Start
2011-02
Primary completion
2013-11
Completion
2013-11

Outcome

Outcome not reported

Stopped: “Product no longer on the market”

Drugs

EvaluationDrugModalityDoseRoute
Subject PureGen Osteoprogenitor Cell Allograft Cell therapy — —